Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCWB NYSE:MTNB NASDAQ:PCSA NASDAQ:SLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCWBHCW Biologics$5.72+0.7%$4.41$2.77▼$100.80$12.22M0.664.53 million shs179,723 shsMTNBMatinas Biopharma$1.82-10.8%$1.21$0.47▼$4.49$9.26M1.32437,608 shs44,875 shsPCSAHeatwurx$0.19-10.7%$0.22$0.15▼$1.50$10.65M1.325.21 million shs3.67 million shsSLRXSalarius Pharmaceuticals$5.76+1.4%$10.01$4.76▼$108.00$2.90M0.45137,916 shs40,754 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCWBHCW Biologics+0.70%+65.80%+33.02%-27.59%-70.82%MTNBMatinas Biopharma-10.78%-14.55%+117.70%+124.14%+880.08%PCSAHeatwurx-10.68%-13.30%-12.09%-35.38%-86.78%SLRXSalarius Pharmaceuticals+1.41%-0.17%-50.95%-50.77%-76.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCWBHCW Biologics2.5189 of 5 stars3.53.00.00.03.11.70.0MTNBMatinas Biopharma0.6384 of 5 stars0.05.00.00.01.10.00.6PCSAHeatwurx2.5393 of 5 stars3.34.00.00.01.61.70.6SLRXSalarius Pharmaceuticals0.144 of 5 stars0.02.00.00.02.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCWBHCW Biologics 3.00Buy$35.00511.89% UpsideMTNBMatinas Biopharma 2.00HoldN/AN/APCSAHeatwurx 2.50Moderate Buy$2.00958.20% UpsideSLRXSalarius Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SLRX, PCSA, MTNB, and HCWB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025PCSAHeatwurxZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/30/2025PCSAHeatwurxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $2.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCWBHCW Biologics$2.57M4.79N/AN/A($0.02) per share-286.00MTNBMatinas BiopharmaN/AN/AN/AN/A$4.43 per shareN/APCSAHeatwurxN/AN/AN/AN/A$0.12 per shareN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/A($1.63) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCWBHCW Biologics-$30.02M-$14.04N/A∞N/A-1,368.55%N/A-40.72%N/AMTNBMatinas Biopharma-$22.94M-$3.89N/A∞N/AN/A-123.06%-94.28%N/APCSAHeatwurx-$11.85M-$2.32N/AN/AN/AN/A-342.36%-243.48%10/29/2025 (Estimated)SLRXSalarius Pharmaceuticals-$5.58M-$43.48N/A∞N/AN/A-556.47%-192.35%11/12/2025 (Estimated)Latest SLRX, PCSA, MTNB, and HCWB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025HCWBHCW Biologics$1.80-$6.79-$8.59-$6.79$7.00 million$0.01 million8/12/2025Q2 2025SLRXSalarius Pharmaceuticals-$33.00-$0.45+$32.55-$0.45N/AN/A8/7/2025Q2 2025PCSAHeatwurx-$0.23-$0.25-$0.02-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCWBHCW BiologicsN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCWBHCW BiologicsN/A0.110.11MTNBMatinas BiopharmaN/A5.535.53PCSAHeatwurxN/A3.453.45SLRXSalarius PharmaceuticalsN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCWBHCW Biologics2.96%MTNBMatinas Biopharma11.77%PCSAHeatwurx91.93%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipHCWBHCW Biologics42.70%MTNBMatinas Biopharma4.60%PCSAHeatwurx2.40%SLRXSalarius Pharmaceuticals1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCWBHCW Biologics402.15 million1.23 millionNot OptionableMTNBMatinas Biopharma305.09 million4.60 millionN/APCSAHeatwurx2050.35 million49.14 millionNot OptionableSLRXSalarius Pharmaceuticals20510,000504,000Not OptionableSLRX, PCSA, MTNB, and HCWB HeadlinesRecent News About These CompaniesSalarius Pharmaceuticals Files Prospectus for Stock OfferingAugust 27 at 2:18 AM | msn.comSalarius Pharmaceuticals (NASDAQ:SLRX) Stock Rating Upgraded by Wall Street ZenAugust 24, 2025 | americanbankingnews.comSalarius Pharmaceuticals Inc (SLRX) - Investing.comAugust 20, 2025 | investing.comSalarius Pharmaceuticals Appoints New Acting CEOAugust 19, 2025 | msn.comSalarius Pharmaceuticals files $50M mixed securities shelfAugust 16, 2025 | msn.comSalarius Pharmaceuticals trading halted, news pendingAugust 16, 2025 | msn.comSalarius Pharmaceuticals Announces Reverse Stock SplitAugust 16, 2025 | msn.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock SplitAugust 14, 2025 | finanznachrichten.deSalarius Pharmaceuticals Announces 1-for-15 Reverse Stock SplitAugust 14, 2025 | globenewswire.comSalarius Pharmaceuticals Raises $3.8M Through Stock SaleJuly 31, 2025 | msn.comSalarius Pharmaceuticals Modifies Security Holders’ RightsJuly 30, 2025 | msn.comSalarius Pharmaceuticals stock soars after Nasdaq extends compliance deadlineJuly 29, 2025 | investing.comSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity StandardJuly 14, 2025 | finance.yahoo.comSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity StandardJuly 14, 2025 | globenewswire.comSalarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role ...July 11, 2025 | morningstar.comMSalarius Pharmaceuticals shareholders approve reverse stock split and share issuanceJuly 10, 2025 | uk.investing.comSalarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published StudiesJuly 10, 2025 | finance.yahoo.comSalarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published StudiesJuly 9, 2025 | globenewswire.comSalarius Granted Nasdaq Extension To Regain Compliance With Listing StandardsJune 18, 2025 | nasdaq.comSalarius Pharmaceuticals faces Nasdaq delisting over rule breachesApril 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLRX, PCSA, MTNB, and HCWB Company DescriptionsHCW Biologics NASDAQ:HCWB$5.72 +0.04 (+0.70%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.57 -0.15 (-2.64%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Matinas Biopharma NYSE:MTNB$1.82 -0.22 (-10.78%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.81 -0.01 (-0.55%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.Heatwurx NASDAQ:PCSA$0.19 -0.02 (-10.68%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.18 -0.01 (-2.65%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.Salarius Pharmaceuticals NASDAQ:SLRX$5.76 +0.08 (+1.41%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.64 -0.13 (-2.17%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
